Btobioinnovation.com  Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com     SPECIAL REPORT 24.07   EMA does not recommend Leqembi for the treatment of Alzheimer’s disease   On July 25, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended against marketing authorisation of BioArtic, Eisai and […]

After decades of trying to develop a treatment for Alzheimer’s disease, Eli Lilly has finally won FDA approval for its drug donanemab, which will be marketed as Kisunla.     An approval was originally expected late last year, but it was delayed twice, including after regulators called for an 11th-hour meeting to discuss the drug’s […]